NGM Bio Announces Topline Results from the CATALINA Phase 2 Trial of NGM621 Portfolio News / By Karina Tin October 17, 2022 NGM Bio Announces Topline Results from the CATALINA Phase 2 Trial of NGM621 Read More »
Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases Portfolio News / By Karina Tin October 6, 2022 Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases Read More »
Nurix Therapeutics Reports Third Quarter Fiscal 2022 Financial Results and Provides a Corporate Update Portfolio News / By Karina Tin October 6, 2022 Nurix Therapeutics Reports Third Quarter Fiscal 2022 Financial Results and Provides a Corporate Update Read More »
eFFECTOR Appoints Mayank Gandhi, M.D., as Chief Business Officer Portfolio News / By Karina Tin September 26, 2022 eFFECTOR Appoints Mayank Gandhi, M.D., as Chief Business Officer Read More »
Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy Portfolio News / By Karina Tin September 26, 2022 Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy Read More »
Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company’s First Mutant-Selective RAS(ON) Inhibitor Portfolio News / By Karina Tin September 22, 2022 Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company’s First Mutant-Selective RAS(ON) Inhibitor Read More »
Neurona Therapeutics Presents Clinical Case Study from First Human Trial of Regenerative Cell Therapy, NRTX-1001, in Adults with Drug-Resistant Focal Epilepsy Portfolio News / By Karina Tin September 21, 2022 Neurona Therapeutics Presents Clinical Case Study from First Human Trial of Regenerative Cell Therapy, NRTX-1001, in Adults with Drug-Resistant Focal Epilepsy Read More »
Carmot Therapeutics Announces Significant Leadership Team Expansion with Anne Phillips, MD, FRCPC Previously SVP Novo Nordisk, Joining the Board of Directors and Heather Turner, J.D. Joining as COO Portfolio News / By Karina Tin September 21, 2022 Carmot Therapeutics Announces Significant Leadership Team Expansion with Anne Phillips, MD, FRCPC Previously SVP Novo Nordisk, Joining the Board of Directors and Heather Turner, J.D. Joining as COO Read More »
Atavistik Bio Announces Formation of Scientific Advisory Board Portfolio News / By Karina Tin September 20, 2022 Atavistik Bio Announces Formation of Scientific Advisory Board Read More »
eFFECTOR Therapeutics Doses First Patient in Second Cohort of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19 Portfolio News / By Karina Tin September 14, 2022 eFFECTOR Therapeutics Doses First Patient in Second Cohort of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19 Read More »
